Evidence map›Paper›PMID 42703435›Full record

ReviewIranian journal of basic medical sciences2026

Principles and regulatory pathways of exosome-based products in wound healing: Insights from the Iranian Food and Drug Administration guideline.

Delnavaz Nazari, Banafsheh Heidari, Nazanin Akbari, Zahra Soleymani

Abstract readReview
In one paragraph

Review in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Delnavaz NazariDepartment of Veterinary Basic Sciences, SR.C., Islamic Azad University, Tehran, Iran.
Banafsheh HeidariDepartment of Regenerative Medicine in Wound Healing, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran.
Nazanin AkbariDepartment of Biology, Shahid Beheshti University, Tehran, Iran.
Zahra SoleymaniDepartment of Veterinary Basic Sciences, SR.C., Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wound healing is a critical clinical challenge, particularly for chronic and refractory wounds complicated by infection, necrosis, amputation, and death. Recently, cell derivatives, particularly extracellular vesicles (EVs) from mesenchymal stem cells, have emerged as promising cell-free therapeutic agents in regenerative medicine. The review aims to introduce small extracellular vesicles (sEVs) as a next-generation therapeutic strategy and to describe different EV types according to the Global Regulatory Framework (GRF). We also compare techniques for isolating, purifying, and characterizing sEVs and evaluate sEV-based therapies in tissue engineering, focusing on their scope and limitations.A narrative review of the literature was conducted, focusing on preclinical and clinical studies investigating EV-based therapies in wound healing, along with an investigation of the GRF, particularly the Iranian Food and Drug Administration (IFDA) guideline on EVs. The IFDA has recently established a framework for categorizing extracellular particles and highlighting the structural complexity and functional diversity of EVs. sEVs demonstrate significant therapeutic potential for wound repair by promoting angiogenesis, enhancing epithelialization, modulating inflammation, and accelerating tissue remodeling. To enhance the stability and therapeutic lifespan of sEVs, advanced delivery systems, including hydrogels, nanofibers, and biomatrices, are used to preserve structural integrity, physicochemical stability, biological functionality, and morphological characteristics, and to control their release at the injury site. EV-based therapies represent a promising and versatile approach in regenerative medicine for wound healing. Despite challenges in isolation, characterization, scalable manufacturing, and regulatory approval, sEV-based therapeutics offer a biocompatible, cost-effective, and versatile platform that bridges nanotechnology and regenerative medicine.

Indexed as

Biological productsDrug approvalExosomesExtracellular vesiclesGovernment regulationNanomedicineRegenerative medicineWound Healing

Identifiers

PMID42703435
PMCPMC13546497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.